While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

What Happened? A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1 ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

Ahead of the April 23 release of her book, Closer Together: Knowing Ourselves, Loving Each Other, Grégoire Trudeau sat down with Yahoo Canada for an emotional conversation. She spoke about mental ...

Maria Billington describes Wolverhampton's Gatis Community Space as a "green oasis in a urban jungle". Hidden away in the ...

“Los Angeles General Medical Center, a public hospital run by the L.A. County Department of Health Services, is seeking the ...

For some, Osteoboost might initially evoke TV informercials for gadgets that promise to shock people’s abdominal muscles into ...

Salem Investment Counselors Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities ...

The Supreme Court is siding with a teenage girl with a rare form of epilepsy in a ruling that could make it easier for families like hers to go to court over access to education ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...